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Abstract
Study design: Severe falciparum malaria in children was studied as part of the characterization of
the Kassena-Nankana District Ghana for future malaria vaccine trials. Children aged 6–59 months
with diagnosis suggestive of acute disease were characterized using the standard WHO definition
for severe malaria.
Results: Of the total children screened, 45.2% (868/1921) satisfied the criteria for severe malaria.
Estimated incidence of severe malaria was 3.4% (range: 0.4–8.3%) cases per year. The disease
incidence was seasonal: 560 cases per year, of which 70.4% occurred during the wet season (June-
October). The main manifestations were severe anaemia (36.5%); prolonged or multiple
convulsions (21.6%); respiratory distress (24.4%) and cerebral malaria (5.4%). Others were
hyperpyrexia (11.1%); hyperparasitaemia (18.5%); hyperlactaemia (33.4%); and hypoglycaemia
(3.2%). The frequency of severe anaemia was 39.8% in children of six to 24 months of age and 25.9%
in children of 25–60 months of age. More children (8.7%) in the 25–60 months age group had
cerebral malaria compared with 4.4% in the 6–24 months age group. The overall case fatality ratio
was 3.5%. Cerebral malaria and hyperlactataemia were the significant risk factors associated with
death. Severe anaemia, though a major presentation, was not significantly associated with risk of
death.
Conclusion: Severe malaria is a frequent and seasonal childhood disease in northern Ghana and
maybe an adequate endpoint for future malaria vaccine trials.
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Background
Globally, an estimated 350–500 million clinical malaria
episodes occur annually; most of these are caused by
infection with Plasmodium falciparum with more than one
million deaths each year. About 60% of the clinical epi-
sodes and more than 80% of the deaths occur in young
children in Africa, south of the Sahara, where malaria
accounts for 25–35% of all outpatients visits, 20–45% of
hospital admissions and 15–35% of hospital deaths [1,2].
Despite the introduction in recent years of more rational
antimalarial regimens and the increasing use of the most
rapidly parasiticidal artemisinin derivatives [3,4], the
malaria risk and mortality has not seen significant reduc-
tions yet [5,6]. Studies on factors associated with
increased risk of developing severe malaria and death,
may provide additional understanding of the course of
severe malaria, and, eventually, lead to improved case
management, and the development of drugs and vaccines
for malaria.
Moreover, this requires the establishment of appropriate
case definitions and meaningful trial endpoints for future
testing in endemic sites [7]. Several studies, at various sites
in Africa, have attempted to delineate the epidemiology of
clinical malaria, and the data have shown significant var-
iability across various transmission zones [8-12]. There is,
therefore, a need for more site-specific data in order to
appreciate the complete clinical and epidemiological pic-
ture needed for efficient testing of candidate malaria vac-
cines and other control tools in different endemic sites.
Young children with severe malaria enrolled in order to
study the course of severe malaria in the Kassena-Nankana
district of northern Ghana, a site being characterized for
future malaria vaccine trials.
Methods
Study setting
The study was carried out in the Navrongo War Memorial
Hospital (NWMH) located in the Kassena-Nankana Dis-
trict (KND) of northern Ghana. The KND lies in the sahe-
lian savannah and covers about 1,674 square kilometres
of land with a population of approximately 143,000
under continuous demographic surveillance [13]. The
area is characterized by two distinct seasons; a rainy sea-
son from June to October and a hot dry season from
November to May. Annual rainfall averages 850 mm and
means daily temperature ranges from 20°C to 40°C.
Malaria transmission is perennial with distinct seasonal
patterns. The peak malaria transmission coincides with
the period of major rains while the dry season has low
rates of malaria infection [14]. Infection is attributed
mostly to P. falciparum with Anopheles funestus and Anoph-
eles gambiae as the principal vectors [15]. The estimated
annual entomological inoculation rates [15], parasite
prevalence [14], malaria attack rates [16] and antimalaria
efficacy rates [17] have been well studied.
Study design and participants
All children between six and 59 months of age, who were
admitted at the NWMH with diagnosis suggestive of acute
disease, from August to December 2002 and from May
2003 to April 2004, were evaluated for inclusion in the
study. Criteria for diagnosis and enrolment included the
standard WHO definition for severe malaria [18,19].
Those who satisfied the selection criteria including resi-
dence in the KND and whose parents voluntarily gave
informed consent were enrolled. Parents were interviewed
about the presenting symptoms and study physicians doc-
umented findings of clinical examination including
weight and vital signs. In addition, the course of illness,
including daily vital signs and peripheral blood parasitae-
mia, were documented for each study child from the time
of enrolment to the time of exit from the hospital. Patients
were seen daily while on admission and on day 7, 10 and
14 following discharge from the hospital. Those who were
alive on day 14 after admission were considered to have
survived the acute severe malaria episode. Parents of sur-
viving children were interviewed at home on days 7, 10
and 14 to determine whether their child or ward remained
in good health. Participants completed the study by satis-
fying all study entry requirements and providing all spec-
imens and interviews as provided for by the protocol. This
report describes the clinical and laboratory characteristics
as well as the prognostic indicators for children admitted
with severe malaria.
Laboratory procedures
At enrolment, peripheral malaria blood smears, full blood
count and blood lactate were done for all participants.
While on admission, blood smears were taken for daily
parasitological examinations until two consecutive
smears were aparasitaemic, and on days 7 and 14 from the
day of enrolment. Thick and thin blood films were made,
thin film fixed with methanol and both thin and thick
film stained with 10% Giemsa and examined for malaria
parasites. Parasite density was measured as the number of
parasites per 200 leucocytes on a thick film and converted
into parasites per microlitre of blood based on the partic-
ipants total white cell count obtained at enrolment. Ten
percent of both positive and negative slides were ran-
domly selected and read by an independent microscopist
as a quality control check. Two hundred high power fields
of the thick films were examined at 1,000× magnification
before assigning a negative result. Whole blood specimens
were analysed for full blood count using automated ABX
Micros 60-OT haematology analyser; serum creatinine,
blood glucose and transaminases levels were determined
using Micro lab 200, and blood lactate using YSI lactate
analyzer.Malaria Journal 2007, 6:96 http://www.malariajournal.com/content/6/1/96
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Clinical management
Children were treated using a uniform protocol based on
standard recommendations[19] consisting of parenteral
quinine at 20 mg/kg loading dose followed by 10 mg/kg
maintenance dose every 12 hours until the patient was
able to swallow, at which point she or he was switched to
an oral dose of 10 mg/kg every eight hours to complete a
seven day course of treatment. In addition to the specific
treatment for P. falciparum infection, children received
supportive therapy in terms of haemotransfusion for
severe anaemia, intravenous glucose for hypoglycaemia
and intravenous fluid for severe dehydration. Paracetamol
suppositories were administered for pyrexia, diazepam for
seizures, antibiotics for bacterial infections, and nasal oxy-
gen for respiratory distress as per standard local practice.
Approvals
Ethical approval for this study was obtained from the fol-
lowing ethical committees: the Ghana Health Service, the
Navrongo Health Research Centre, the Noguchi Memorial
Institute for Medical Research and the United States Naval
Medical Research Center.
Data and statistical analysis
All study data were captured on a structured case report
form bearing subject demographic and identification
numbers. All forms were reviewed before being double
entered onto a computer. Statistical analyses were carried
out with Epi Info 6.04 (ENSP-Epiconcept-InVS, Corp.)
and Stata statistical software (version 7.0, Stata Corpora-
tion, College Station, Texas, USA). Continuous and nor-
mal distributed data were compared by two-tailed
student's t-test and proportions compared with χ2 tests
with Yates' correction or Fisher's exact test. Basic statistics
were calculated for the baseline characteristics- sex, age
group, weight, fever, parasitaemia, presenting symptoms,
malaria prevention practices and area of residence. Point
estimates using proportions and means, and 95% confi-
dence intervals were computed for the clinical and labora-
tory features. Significant differences were tested using
confidence intervals of the difference or odds ratio and the
corresponding (95%) confidence intervals and p-values. A
p-value of ≤ 0.05 was considered statistically significant.
Results
Baseline characteristics
Out of the total of 1,921 children screened, 73.1% (1405/
1921) had a positive parasitaemia and, of these, 61.8%
(868/1405) satisfied the criteria for severe falciparum
malaria. About 56% (490/868) of the total enrolees were
males and majority of 76% [661/868] aging below 24
months of age (Figure 1). The average age and weight were
respectively 18.9 months (range: 6–59) and 8.9 kilograms
[95%CI 8.7, 9.1]. At baseline, the mean haemoglobin and
geometric mean parasite density were 6.1 g/dl [range 1.8–
13.7] and 26903-parasites/µl [95%CI 22026, 32860]
respectively. The proportion with fever (axillary tempera-
ture ≥ 37.5°C), thrombocytopaenia and leucocytosis were
77.3% (671/868), 52.1% (452/868) and 47.7% (414/
868), respectively. Other enrolment symptoms were vom-
iting (66.6%), cough (60.7%), shaking chills (57.5%),
breathing difficulty (57.4%), lethargy (52.4%), diarrhoea
(43.0%), convulsion (39.1%), and inability to eat 38.2%.
Reported insecticide-treated bed net (ITN) use and prior
malarial chemotherapy were 58.8% (510/868) and
49.5% (430/868) respectively.
Major clinical and prognostic features
Cerebral malaria
In all, 47 (5.4%) of the children had cerebral malaria
(Blantyre coma score < 3), the frequency of cerebral
malaria in the 25–60 months old was 8.7% [95% CI
5.2,13.4] compared to 4.4% [95% CI 2.9, 6.2] in 6–24
months olds. Proportions of boys and girls with cerebral
malaria were similar (5% (23/490) vs. 6% (24/378).
Fewer children with cerebral malaria had severe anaemia
compared to those without cerebral malaria (28%(13/47)
vs. 37% (302/816). Again a higher proportion of children
with cerebralmalaria had higher respiratory distress than
those without (70.2% vs. 21.3%). The mean of haemo-
globin, serum lactate and blood glucose among cerebral
malaria patients were 7.0 g/dl, 8.5 mmol/l, and 6.2
mmol/l, respectively. The total case fatality ratio among
children with cerebral malaria was 29.8% (14/47).
Severe anaemia
This was the most frequent manifestation, 36.5% (315/
863), and was more prevalent in males than females
[40.2% vs. 31.6%], in 6–24 month olds than 25–60 olds
Age-specific distribution of severe malaria and anaemia in the  northern Ghana Figure 1
Age-specific distribution of severe malaria and anae-
mia in the northern Ghana. Children aged 6–59 months 
with severe malaria by WHO criteria (white) and severe 
anaemia (black).
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[39.8 vs. 25.9], Figure 1, and in those not using ITNs than
those using ITNs [41.9% vs.32.7%]. The overlap of severe
anaemia with cerebral malaria and respiratory distress
were 4.1% (13/315) and 38.7% (122/315) respectively
(Figure 2). About 87% (274/315) of children with severe
anaemia at enrolment received a blood transfusion. The
frequencies of severe anaemia in children residing in the
irrigated and non-irrigated areas were 29.9(38/127) and
37.6(277/736) respectively. The total case fatality ratio
among children with severe anaemia was 3.5%(11/315)
but for those who had no other associated severe malaria
pathology, total recovery was achieved (Figure 2).
Respiratory distress
About 24% (212/868) of the participants presented with
respiratory distress. Children with respiratory distress
were likely to be younger (mean age, 18 months), and had
higher geometric mean parasite density (22,026 parasites/
microlitre)(Table 1). Again respiratory distress was signif-
icantly associated with severe anaemia (OR 3.3 95%CI
2.3, 4.6) and hyperlactataemia (OR 2.3 95%CI 1.5,3.2).
The case fatality ratio of respiratory distress was 8.5%
[95% 5.1,13.1]. The ratio was significantly increased to
23.8% and 33.3% if the respiratory distress overlapped
with cerebral malaria or cerebral malaria plus severe anae-
mia respectively (Figure 2).
Other severe malaria manifestations at enrolment were
multiple or prolonged convulsions 21.6% (187/864),
hyperlactataemia 33.4% (249/746), hyperparasitaemia
18.5% (161/868) and hypoglycaemia 3.2% (24/761).
Factors associated with malaria death
The overall study case fatality ratio was 3.5 (30/868). The
ratio was similar in males and females (3.3% vs. 3.7%)
and in 6–24 and 25–59 month's olds (3.3 vs. 3.9%). Their
baseline presentations were: cerebral malaria 46.7% (14/
30), severe anaemia 36.7% (11/30), respiratory distress
60%(18/30) and hyperlactataemia 61.5(16/26). Bivariate
analysis (Table 2) showed that cerebral malaria, hypogly-
caemia, respiratory distress and hyperlactaemia were the
risk factors associated with most deaths, but logistic
regression analysis showed that only cerebral malaria
OR= 12.9(95% CI 4.1,40.8) and hyperlactataemia OR =
1.2 (95%CI 1.1, 1.3) were risk factors associated with fal-
ciparum malaria death.
Incidence of severe malaria
To estimate severe malaria incidence in the population, a
mid year population of children 6–59 months old in the
district from the Navrongo demographic surveillance
database and the total cases from May 2003 to April 2004
were used. In all, there were 16,298 children (aged 6 to 59
months) and 560 severe malaria cases giving an overall
incidence of 0.034 cases per year. The incidence was high-
est in the age group, 6–11 months and lowest in the 48–
59 month old (Table 3).
Table 1: Characteristics of the major clinical subgroups.
Parameters Cerebral Malaria (n = 47) Severe Anaemia (n = 315) Respiratory Distress (n = 212)
Males, n (%) 23(48.9) 202(61.8) 117(55.2)
6–24 months, n (%) mean age 21.6 (13.1) 16.5(10.0) 17.9(11.3)
Mean haemoglobin, g/dl (SD) 7.0(2.6) 3.8(0.8) 5.2(2.3)
Mean blood lactate, mmol/L(SD) 8.5(5.7) 5.8(4.1) 6.6(4.9)
*GMPD, parasites/µL 15223 15361 22026
Mean blood glucose, mmol/L (SD) 6.2(3.6) 5.0(1.8) 5.1(2.1)
Hypoglycaemia, n (%) 6(12.8) 8(2.5) 18(8.5)
Hyperlactataemia, n (%) 34(72.3) 142(45.1) 101(47.6)
Hyperparasitaemia, n(%) 8(17.0) 34(10.8) 33(15.6)
Hyper pyrexia, n (%) 1(2.1) 12(3.8) 28(13.2)
* GMPD = geometric mean parasite density
Venn diagram of proportions, overlap and mortality of  severe malaria major clinical subgroups Figure 2
Venn diagram of proportions, overlap and mortality 
of severe malaria major clinical subgroups. Total 
number of major clinical subgroups in parenthesis and, mor-
tality is given as percentage.
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Seasonal variation
Of the 560 cases of severe malaria enrolled during the one
year period [May 2003 to April 2004], 70.4% (394/560)
were enrolled in June-October (the high transmission sea-
son) and 29.4%(166/560) in November-May (low trans-
mission season). The highest number of cases, 127
(22.7%) were enrolled in September and the lowest, 6
(1.1%) in April (Figure 3). Though more cases of severe
anaemia (72%) occurred during the high transmission
season, the proportions of severe anaemia in the high and
low seasons were similar (35.5% vs. 33.1% p-value >
0.05). About 71% (22/31) of cerebral malaria cases
occurred in the wet season compared to 29% (9/31) in the
dry season. The geometric mean parasite density in the
high season was 37,876 parasites/µl [95%CI 31,069/
46,174] compared to 21,473-parasites/µl [95%CI 15,564/
29,624] in the low season. The prevalence of hyperparasi-
taemia was also greater in the high transmission season
than in the low season (22.1% versus 7.4%, p-value <
0.001). The case fatality ratios during the high and low
seasons were 4.2% (7/166) and 1.8% (7/394), respec-
tively.
Discussion
As part of malaria characterization studies in northern
Ghana in preparation for malaria vaccine trials severe
malaria among young children was studied. The results
showed that significant population and numbers of severe
P. falciparum malaria exist in the Kassena-Nankana Dis-
trict of northern Ghana that may represent an adequate
vaccine trial endpoint. Severe malaria, as a vaccine trial
endpoint offers several advantages over other endpoints
that could be used in future malaria vaccine efficacy trials
[20,21]. Even though mortality impact is the most impor-
tant public health measure of any vaccine efficacy, it rep-
resents a smaller proportion of all disease burdens and
will, thus, require large sample size in future trials [22].
Also, in many malaria endemic countries, assignment of
causes of deaths may present sensitivity and specificity
problems that may lead to misclassification and reduction
of the statistical power of any trial with mortality as an
endpoint[23]. On the other hand, it is difficult to define
and differentiate mild malaria and infection as endpoints
from many of the other common febrile illnesses in most
endemic areas [24,25]. Again the comparative ease of
using the established case definitions of severe malaria
[18] and the fact that most children diagnosed as having
the disease have worse prognoses than those with mild
disease makes severe malaria a better trial endpoint. Well-
defined severe malaria, therefore, bridges the gap of being
common enough for a reduction to be measurable and as
Seasonal prevalence of severe malaria and anaemia in the  Kassena-Nankana district of Ghana Figure 3
Seasonal prevalence of severe malaria and anaemia 
in the Kassena-Nankana district of Ghana. WHO crite-
ria of severe malaria (white) and severe anaemia (black) by 
month of the year.
0
20
40
60
80
100
120
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Month of the year
N
u
m
b
e
r
o
f
c
a
s
e
s
severe malaria
Severe anaemia
Table 2: Prognostics indicators at the time of enrolment
Outcome Prevalence,n(%) Fatalities, n(%) OR χ2 95% CI P-value
Cerebral malaria 47 (5.4) 14(29.8) 21.3 103.3 8.7,50.7 0.000
Severe anaemia 315 (36.5) 11(3.5) 1.02 0.02 0.45,2.28 0.88
Respiratory distress 212 (24.4) 18 (8.5) 4.9 20.7 2.1,11.3 0.000
Hyperlactataemia 290 (33.4) 19 (6.6) 3.6 20.7 1.6,8.6 0.000
Hypoglycaemia 33 (3.8) 4(12.1) 4.3 7.7 1.0,13.5 0.005
Table 3: Age-specific incidence of severe malaria in the KND 
(2003–2004)
Age group 
(Months)
Mid year 
population 
(% of total)
Number of 
cases 
(% of total)
Estimated incidence 
of severe malaria.
6–11 1632 (10.0) 136 (24.2) 0.083
12–23 3474 (21.3) 262 (46.8) 0.075
24–35 3536 (21.7) 105 (18.8) 0.030
36–47 3816 (23.4) 41 (07.3) 0.011
48–59 3840 (23.6) 16 (02.9) 0.004
Total 16298 (100) 560 (100) 0.034Malaria Journal 2007, 6:96 http://www.malariajournal.com/content/6/1/96
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important as possible to predict malaria-associated mor-
tality in endemic sites [21]. For instance, in the recent
study in Mozambique, RTSS/AS02A vaccine showed a sig-
nificant protection against severe malaria [26].
The current study showed that over a period of fifteen
months, 868 severe cases were recruited, with most of the
cases (76%) being children between 6–24 months old,
with a significant decreasing trend towards increasing age
(Figure 1). As in other settings the predominant manifes-
tation was severe malarial anaemia. Other clinical and
laboratory manifestations were also consistent with what
have earlier been reported in other endemic settings [9-
12]. Using the total number of cases of severe malaria in
one year and the mid year population of children at risk
in the study area, the annual incidence of severe malaria
was estimated to be 3.4% (95% CI 3.1,3.7): ranging from
0.4% in 48–59 months old to 8.3% in 6–12 months olds
(Table 3). This is significantly higher than the 2.3%
reported in a similar setting in another part of West Africa
[21], even though this represent only hospital cases
instead of census as in that study [21]. This suggesting that
this finding may even be an underestimation, as some
children might have died at home during the period since
almost all cases of untreated severe and complicated
malaria are fatal.
The overall case fatality ratio in this study was 3.5%; this
was similar by gender (3.3% vs. 3.7%) and by the age
groups (3.3% vs. 3.9%). The independent prognostic
indicators were cerebral malaria and hyperlactataemia
confirming the fact that in severe malaria, neurological
involvement and metabolic dysfunction are the factors
that are most associated with poor outcome [9,27,28].
Severe anaemia, though the most frequent presenting fea-
ture, was a poor predictor of death [29,30], perhaps
because most severe malaria anaemia children received
timely blood transfusion. Despite this, severe anaemia
will be an important vaccine trial endpoint because of its
frequency, especially in children and because of the ease
with which it can be measured with certainty in field situ-
ations.
Further significant seasonal variation of severe malaria
was recorded over the period. The highest prevalence
occurred in the months of July to December (during the
rainy season). The observed pattern points to the fact that
increase in vector breeding following the raining season is
responsible for the upsurge in the malarial cases and sup-
ports an earlier transmission studies [15]. In malaria
endemic areas, majority of malaria death and morbidity
occur during the peak transmission seasons. As such, the
intermittent preventive treatment approaches to malaria
control during this intense period [31] could impact on
reducing disease burden. Such preventive measures could
reduce the risk of severe malaria and subsequently mini-
mize its effect as a vaccine trial endpoint. For instance the
results showed that ITNs usage was high; patients not
using ITNs had higher incidence of severe anaemia and
cerebral malaria compared to those using ITNs. These
considerations need to be factored in when estimating
sample size for future vaccine studies.
Conclusion
Major conclusions can be drawn from this study. First,
severe malaria in the area occurs frequently in the first 30
months of life, the predominant feature being severe
anaemia. Most of the severe malaria occurs in the high
transmission and short period, which suggest that the area
can effectively support intervention studies including vac-
cine trials in the prevailing short, but intensive, transmis-
sion season.
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